followup research: ado-rbm-myriad

this is just a follow up on research on RBM for those that read my post last year.

link between RBM n ADO dates back to 2006, collaboration in the luminex assays.

RBM has been acquired by myriad this year.



flipping thru the 2006 ann from ADO, i still dun know what is the 1billion market cap company ADO was partnering with (see 9jan2006 ann). if anyone does know, kindly leave a msg. Thanks)



ok back to RBM, heres a little article about them.

Recently, Rules-Based Medicine (RBM) achieved a significant milestone in a companion diagnostic development program with Roche (RHHBY). A biomarker pattern was identified using samples from a clinical trial conducted by Roche that could predict disease progression or monitor the effectiveness of a compound in its CNS pipeline.

Based on the positive results so far, Roche has decided to continue with the commercial development of the product and could result in future milestone and royalty payments to RBM.

Earlier, in April 2011 Myriad Genetics? (NASDAQ:MYGN) decided to acquire Texas based, privately-held RBM for $80 million in cash. This deal, expected to close by the end of May, would expand Myriad?s portfolio to take into its ambit psychiatric disorders, infectious diseases and inflammatory diseases.

According to Myriad, apart from strengthening its strong oncology pipeline it would also have access to RBM?s pipeline that includes tests for anti-psychotic drug safety, hepatitis C drug response and detection of kidney damage in diabetes patients.

Myriad is aiming at establishing itself as a strong player in the companion diagnostic market. To establish Bracanalysis as a companion diagnostic for PARP inhibitors, Myriad has got into agreement with Abbott Laboratories(NYSE:ABT), BioMarin Pharmaceuticals (NASDAQ:BMRN) and AstraZeneca(AZN). PARP inhibitor is a promising oncology drug candidate under development and these drugs could be on the market within the 2012-2013 timeframe.

The proposed acquisition of RBM would place Myriad as a leader in this arena based on the former?s proprietary protein technology and its 550 immunoassays. RBM has provided custom assay development and companion biomarker discovery for several pharmaceutical companies. Through these collaborations, RBM has obtained companion diagnostic rights to many of the drugs under development.